Clinical trials: Orthomyxoviridae Infections
Influenza Human
Clinical Validation of the Point-of-Care MSD Influenza Test
The primary objective of this study is to evaluate the performance of the MSD® Influenza Test in detecting influenza A and influenza B in subjects presenting with influenza-like-illness (ILI).
- Trial name
- NCT00863343
- Testing
- Public Health Notification
- Where
- 3 sites in United States
- Volunteers
- 391 people
- Sponsor
- Meso Scale Diagnostics, LLC.
Immunization, Human Influenza
Study of Yili Mei Yi Tian Active Lactobacillus Drink to Improve Immunity and Digestive System
Study on Evaluating the Promote Effect of Yili Mei Yi Tian Active Lactobacillus Drink on Immunity and Physical Intestinal Canal
- Conditions
- Immunization, Human Influenza, Common Cold, Constipation
- Trial name
- NCT01677715
- Testing
- Yili "Mei Yi Tian" active lactobacillus drink, recombined milk drink contains no lactobacillus
- Where
- 2 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Inner Mongolia Yili Industrial Group Co., Ltd
Healthy
Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Infants
The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG Quadrivalent Seasonal Influenza Vaccine) in healthy infants from 6 months to under 3 years of age(≥ 6…
- Trial name
- NCT04381689
- Testing
- IL-YANG FLU Vaccine Prefilled Syringe INJ., Fluarix Tetra Pre-filled Syringe
- Where
- 2 sites in South Korea
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Influenza
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in non-elderly and elderly adults.
- Trial name
- NCT00973349
- Testing
- MF59-eH1N1_f
- Where
- 21 sites in United States, Mexico
- Volunteers
- 2,719 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older
The study will evaluate the safety, tolerability and immunogenicity of different doses and types of Influenza Vaccine in healthy elderly subjects.
- Trial name
- NCT00848848
- Testing
- Trivalent Influenza Vaccine, Trivalent Influenza Vaccine + high A, Trivalent Influenza Vaccine + ¼ dose adjuvant
- Where
- Belgium
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Safety and Efficacy of Oral Colostrum Derived Anti Influenza Antibodies in Healthy Volunteers
Administration of colostrum enriched with anti-Flu antibodies may alter host's response to the flu virus.
- Trial name
- NCT01026350
- Testing
- colostrum enriched with anti flu antibodies
- Where
- Israel
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Emergencies, Epidemic Disease
Impact of the Qatar 2022 FIFA World Cup on PED Use and Misuse Patterns
A retrospective cohort study to explore the impact of the FIFA World Cup 2022 Qatar on paediatric emergency department attendance at two tertiary centres during unprecedent winter viral epidemics.
- Conditions
- Emergencies, Epidemic Disease, Pediatric ALL, Electronic Medical Record
- Trial name
- NCT05818215
- Testing
- NO intervention
- Where
- Switzerland
- Volunteers
- 18,000 people
- Sponsor
- Pediatric Clinical Research Platform
Immune Response
Plant Stanol Esters and Influenza Vaccination
Plant stanols are known to lower low-density lipoprotein cholesterol (LDL-C). However, recent studies have suggested that these compounds also beneficially influence the immune system, e.g.
- Trial name
- NCT05706350
- Testing
- Influenza vaccine, Plant stanol soft chews (2g per day), Plant stanol soft chews (3g per day)
- Where
- Netherlands
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Influenza, Vaccine
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
The clinical study will evaluate safety and the immune response of a prime- boost regimen with a live attenuated influenza vaccine (LAIV) prime and an inactivated split influenza vaccine (IIV) boost with or without adjuvant.
- Trial name
- NCT03300050
- Testing
- cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV
- Where
- 2 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- PATH
Virus Diseases, Respiratory Tract Infections
Safety of H1N1 Influenza Vaccination in Pregnant Women
Since October 2009, H1N1 influenza vaccine has developed and approved of immunization in population in China. However, there was little epidemiological evidence of safety when vaccinated in healthy pregnant women.
- Conditions
- Virus Diseases, Respiratory Tract Infections, Influenza, Orthomyxoviridae Infections
- Trial name
- NCT01842997
- Testing
- split-virion, non-adjuvanted H1N1 vaccine of 15 μg
- Where
- China
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza, Human, Respiratory Syncytial Virus Infections
Specific Respiratory Infections as Triggers of Acute Medical Events
This study will investigate whether there is a population-level association between circulating respiratory viruses and NHS hospital admissions for acute vascular events using data from national infection surveillance and…
- Conditions
- Influenza, Human, Respiratory Syncytial Virus Infections, Parainfluenza, Rhinovirus
- Trial name
- NCT02984280
- Where
- United Kingdom
- Volunteers
- 787,000 people
- Sponsor
- University College, London
Influenza, SARS-CoV-2 (COVID-19) Infection
Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2
The purpose of this study is to evaluate the virus-specific immune response in people who are symptomatic with confirmed influenza or COVID-19.
- Conditions
- Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host
- Trial name
- WU 437 (NCT06848309)
- Testing
- Bronchoscopy
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Influenza
Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults
This multi-center study will be conducted in the United States with up to 80 healthy adult subjects. Subjects will be scheduled to receive a total of two (2) injections with 1 injection each administered.
- Trial name
- FLU-A (NCT00819013)
- Testing
- Influenza A Vaccine: ACAM FLU-A
- Where
- 3 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza Prevention, Seasonal Influenza
Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
Background: Vaccines help the body learn to fight infections. Some vaccines are combined with adjuvants, which are added substances that make vaccines work better.
- Trial name
- NCT06863142
- Testing
- VRC-FLUMOS0116-00-VP, ALFQ
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 09/10 Season
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT00881842
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
Influenza, Human, Acute Respiratory Infection
Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.
The purpose of this study is to determine whether Ingavirin ® dosed 60 mg daily is effective and safe in the treatment of influenza and other acute respiratory viral infections in 13-17 years old patients.
- Conditions
- Influenza, Human, Acute Respiratory Infection, Viral Infection, Common Cold
- Trial name
- NCT03206346
- Testing
- Ingavirin
- Where
- 5 sites in Russia
- Volunteers
- 161 people
- Sponsor
- Valenta Pharm JSC
Aspergillosis, Influenza
Invasive Pulmonary Aspergillosis and Severe Influenza
Invasive pulmonary aspergillosis (IPA) has been reported in critically ill patients with influenza infection with a highly variable incidence between 1 to 21%.
- Conditions
- Aspergillosis, Influenza, Critical Illness
- Trial name
- ASPERGIGRIPP (NCT04232956)
- Where
- 4 sites in France
- Volunteers
- 478 people
- Sponsor
- University Hospital, Brest
Rheumatoid Arthritis
Standard Versus High Dose Inactivated Influenza Vaccine in RA
Patients with rheumatoid arthritis have increased risk of seasonal influenza and influenza-related complications but have reduced vaccine immunogenicity.
- Trial name
- IV-RA (NCT02936180)
- Testing
- HD-TIV, SD-QIV
- Where
- Canada
- Volunteers
- 279 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Influenza, Orthomyxoviridae Infections
Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly
Based on the results from a previous formulation/dosage ranging trial, this phase II multicenter, open trial was designed to determine the safety and immunogenicity of two vaccine formulation/dosages with and without adjuvant 21…
- Trial name
- NCT00415129
- Testing
- A/H5N1 inactivated, split-virion influenza virus
- Where
- 4 sites in Belgium, United Kingdom
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine
The purpose of this study is to determine whether having received an H5 vaccine in the past primes the immune system to respond rapidly to another dose of H5 vaccine.
- Trial name
- NCT00240903
- Testing
- Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur)
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)